SPNGNX_logo_hrz.jpg
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
07 juin 2021 07h00 HE | Spinogenix, Inc.
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous system disorders...
SPNGNX_logo_hrz.jpg
Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS)
05 janv. 2021 05h00 HE | Spinogenix, Inc.
SAN DIEGO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Spinogenix, Inc. a preclinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today announced...